Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Scott Johnson

Pulmonary Disease Pinehurst, NC Medical Doctor

NPI 1598739179 CMS profile 1063120

205 Page Rd, Pinehurst, NC 28374

Open in the dashboard

General payments

$24,394

248 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Scott Johnson of Pinehurst, NC is reported in the CMS Open Payments database as having received $24,394 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $17 1
2023 General $99 6
2022 General $87 5
2021 General $139 8
2020 General $16,663 73
2019 General $7,390 155

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Johnson
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Scott Johnson were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Scott Johnson Pulmonary Disease median Middle half National median
2019 $7,390 $377 $109–$1,340 $163
2020 $16,663 $230 $56–$907 $114
2021 $139 $269 $68–$1,072 $132
2022 $87 $390 $100–$1,457 $149
2023 $99 $419 $114–$1,659 $160
2024 $17 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Mylan Specialty L.P. $13,791 44 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $7,559 17 payments
  3. Actelion Pharmaceuticals US, Inc. $517 26 payments
  4. GlaxoSmithKline, LLC. $480 37 payments
  5. Sunovion Pharmaceuticals Inc. $286 20 payments
  6. AstraZeneca Pharmaceuticals LP $231 16 payments
  7. Regeneron Healthcare Solutions, Inc. $181 9 payments
  8. Grifols USA, LLC $175 7 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $153 9 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $104 7 payments
  11. Other $919 56 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,026 12 payments
  2. Consulting Fee $5,160 1 payment
  3. Food and Beverage $3,928 226 payments
  4. Travel and Lodging $1,277 8 payments
  5. Education $4 1 payment
Products named General payments · program years 2019–2024
  1. Yupelri $13,791 44 payments
  2. OFEV $7,521 14 payments
  3. OPSUMIT $527 27 payments
  4. LONHALA MAGNAIR $251 18 payments
  5. TRELEGY ELLIPTA $233 23 payments
  6. DUPIXENT $181 9 payments
  7. NUCALA $179 10 payments
  8. Prolastin-C Liquid $175 7 payments
  9. SYMBICORT $126 9 payments
  10. ANORO $123 12 payments
  11. Other $2,035 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record